代谢综合征的新型标志物
New markers in metabolic syndrome
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:6.303
发表日期:2022
作者:
Da-Hye Son, Hyun-Su Ha, Hye-Min Park, Hae-Young Kim, Yong-Jae Lee
DOI:
10.1016/bs.acc.2022.06.002
摘要
代谢综合征（MetS）在全球范围内呈上升趋势，其临床意义在于与心血管疾病、2型糖尿病和癌症的关联。虽然MetS的发病机制尚未完全阐明，但胰岛素抵抗和源自中心性肥胖的慢性低度炎症被广泛认为是其潜在的基础病理生理机制。因此，胰岛素抵抗指标、脂肪因子和多种炎症标志物被认为是可靠的MetS生物标志物。其他如尿酸、碱性磷酸酶、γ-谷氨酰转肽酶等也已被证实与MetS呈正相关，具有诊断潜力。本文综述了MetS生物标志物的研究进展及实验室分析的系统性方法发展。
Abstract
Metabolic syndrome (MetS) is increasing globally and is clinically significant due to its association with cardiovascular disease, type 2 diabetes and cancer. Although the pathogenesis of MetS has not been clearly elucidated, insulin resistance and chronic low-grade inflammation derived from central obesity are the most widely accepted as underlying pathophysiology. Accordingly, insulin resistance indices, adipokines and various inflammatory markers have been suggested as reliable biomarkers for MetS. Others, such as uric acid, alkaline phosphatase, γ-glutamyl transferase, are also known to positively correlate with MetS and could be diagnostically useful. In this review, we provide a comprehensive overview of MetS biomarkers and the development of a systematic approach to laboratory analysis.